ABCC4: A Drug Target and Potential Biomarker for Multi-Drug Resistance

Target Name: ABCC4

NCBI ID: G10257

ABCC4

ABCC4: A Drug Target and Potential Biomarker for Multi-Drug Resistance

Multi-drug resistance (MDR) is a significant public health issue, affecting millions of patients worldwide. The development of drug-resistant bacteria and viruses has led to the emergence of new treatment options, which are often limited in their effectiveness and can cause significant side effects. The identification of potential drug targets and biomarkers can provide new insights into the treatment of MDR infections and improve the overall quality of life for patients. In this article, we will discuss ABCC4, a protein that has been identified as a potential drug target and biomarker for MDR.

ABCC4: Multidrug Resistance-Associated Protein 4

ABCC4 is a member of the Aquaporin (AQP) family, which includes six structurally similar proteins: AQP1-5 and AQP6. These proteins are involved in water transport and have been implicated in the development of various diseases, including MDR. MDR is a condition in which bacteria and viruses have developed the ability to resist conventional antibiotics, making them ineffective or even life-threatening for the patients.

ABCC4 is expressed in various human organs and is involved in the regulation of water transport in the body. It has been shown to play a crucial role in the development of MDR in various organisms, including bacteria and viruses.

Potential Drug Target: ABCC4

Several studies have suggested that ABCC4 may be a potential drug target for MDR. The identification of ABCC4 as a drug target can lead to the development of new treatments that are effective against MDR bacteria and viruses.

One of the main advantages of targeting ABCC4 is its expression in various human organs, making it a potential target for drug delivery. This can help improve the effectiveness of the treatment and reduce the risk of side effects associated with traditional medications.

In addition, the identification of ABCC4 as a drug target has the potential to improve the overall quality of life for patients with MDR. Currently, there are limited treatment options available for MDR, and the development of new treatments can provide hope for those patients.

Biomarker Potential: ABCC4

ABCC4 has also been identified as a potential biomarker for MDR. The development of drug-resistant bacteria and viruses has led to a decline in the effectiveness of conventional antibiotics, making it difficult for patients to recover from infections. By identifying ABCC4 as a potential biomarker for MDR, researchers may be able to develop new diagnostic tests for the detection of MDR infections and improve the accuracy of current diagnostic methods.

In addition, the identification of ABCC4 as a potential biomarker for MDR has the potential to improve the accuracy of drug development. By identifying new biomarkers for MDR, researchers may be able to identify new treatment options that are effective against drug-resistant bacteria and viruses.

Conclusion

In conclusion, ABCC4 is a protein that has been identified as a potential drug target and biomarker for MDR. The identification of potential drug targets and biomarkers for MDR can provide new insights into the treatment of MDR infections and improve the overall quality of life for patients. Further research is needed to confirm the potential of ABCC4 as a drug target and biomarker for MDR.

Protein Name: ATP Binding Cassette Subfamily C Member 4

Functions: ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds and xenobiotics from cells. Transports a range of endogenous molecules that have a key role in cellular communication and signaling, including cyclic nucleotides such as cyclic AMP (cAMP) and cyclic GMP (cGMP), bile acids, steroid conjugates, urate, and prostaglandins (PubMed:11856762, PubMed:12883481, PubMed:12523936, PubMed:12835412, PubMed:15364914, PubMed:15454390, PubMed:16282361, PubMed:17959747, PubMed:18300232, PubMed:26721430). Mediates the ATP-dependent efflux of glutathione conjugates such as leukotriene C4 (LTC4) and leukotriene B4 (LTB4) too. The presence of GSH is necessary for the ATP-dependent transport of LTB4, whereas GSH is not required for the transport of LTC4 (PubMed:17959747). Mediates the cotransport of bile acids with reduced glutathione (GSH) (PubMed:12883481, PubMed:12523936, PubMed:16282361). Transports a wide range of drugs and their metabolites, including anticancer, antiviral and antibiotics molecules (PubMed:11856762, PubMed:12105214, PubMed:15454390, PubMed:18300232, PubMed:17344354). Confers resistance to anticancer agents such as methotrexate (PubMed:11106685)

The "ABCC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets